STAT Plus: Akcea, a biotech that relies on gene-blocking tech, loses its three top executives in one fell swoop
Three executives at Akcea Therapeutics (AKCA) are out less than a year after the company launched its first FDA-approved drug, Tegsedi, which is intended to treat a rare disease known as hereditary transthyretin amyloidosis, or hATTR.
Paula Soteropoulos, Sarah Boyce, and Jeff Goldberg — the chief executive officer, president and chief operating officer of the company, respectively — all left the company on Wednesday, according to a company press release issued Monday morning.
